Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal doxorubicin plus nab-paclitaxel in head and neck adenoid cystic carcinoma
ChiCTR2100044076Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2020
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegylated liposomal doxorubicin and paclitaxel in Adenoid cystic carcinoma (ACC), sponsored by Chinese PLA General Hospital. Primary endpoint: objective response rate. Started Dec 2020; status: recruiting.
02
Drugs
pegylated liposomal doxorubicinpaclitaxel
03
Conditions
Adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on ChiCTR2100044076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044076.